SYNDAX PHARMACEUTICALS INC (SNDX) Stock Price, Forecast & Analysis
USA - NASDAQ:SNDX - US87164F1057 - Common Stock
SNDX Key Statistics, Chart & Performance
The current stock price of SNDX is 15.04 USD. In the past month the price decreased by -6.35%. In the past year, price decreased by -31.04%.
SNDX Latest News, Press Relases and Analysis
SNDX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.19 | 387.16B | ||
| AMGN | AMGEN INC | 14.64 | 172.38B | ||
| GILD | GILEAD SCIENCES INC | 14.51 | 147.46B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.59 | 104.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.61 | 69.69B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 868.04 | 58.03B | ||
| INSM | INSMED INC | N/A | 40.10B | ||
| NTRA | NATERA INC | N/A | 27.39B | ||
| BIIB | BIOGEN INC | 9.29 | 22.80B | ||
| INCY | INCYTE CORP | 16.51 | 20.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.01 | 20.30B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 36.45 | 15.11B |
Related stock screener links
About SNDX
Company Profile
Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. The company is headquartered in New York City, New York and currently employs 270 full-time employees. The company went IPO on 2016-03-03. The company is focused on developing a pipeline of cancer therapies. Its product candidates include Revuforj and Niktimvo. The company is developing Revuforj, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant AML. The company is also exploring the use of Revuforj as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. The company is also developing Niktimvo, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.
Company Info
SYNDAX PHARMACEUTICALS INC
730 Third Avenue, 9Th Floor
New York City NEW YORK 02451 US
CEO: Briggs W. Morrison
Employees: 270
Phone: 17814191400
SYNDAX PHARMACEUTICALS INC / SNDX FAQ
What does SYNDAX PHARMACEUTICALS INC do?
Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. The company is headquartered in New York City, New York and currently employs 270 full-time employees. The company went IPO on 2016-03-03. The company is focused on developing a pipeline of cancer therapies. Its product candidates include Revuforj and Niktimvo. The company is developing Revuforj, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant AML. The company is also exploring the use of Revuforj as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. The company is also developing Niktimvo, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.
What is the stock price of SYNDAX PHARMACEUTICALS INC today?
The current stock price of SNDX is 15.04 USD. The price increased by 2.38% in the last trading session.
What is the dividend status of SYNDAX PHARMACEUTICALS INC?
SNDX does not pay a dividend.
What is the ChartMill technical and fundamental rating of SNDX stock?
SNDX has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the sector and industry classification for SYNDAX PHARMACEUTICALS INC?
SYNDAX PHARMACEUTICALS INC (SNDX) operates in the Health Care sector and the Biotechnology industry.
Is SYNDAX PHARMACEUTICALS INC (SNDX) expected to grow?
The Revenue of SYNDAX PHARMACEUTICALS INC (SNDX) is expected to grow by 77.13% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the Short Interest ratio of SYNDAX PHARMACEUTICALS INC (SNDX) stock?
The outstanding short interest for SYNDAX PHARMACEUTICALS INC (SNDX) is 25.91% of its float.
SNDX Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to SNDX. When comparing the yearly performance of all stocks, SNDX is a bad performer in the overall market: 71.37% of all stocks are doing better.
SNDX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SNDX. SNDX may be in some trouble as it scores bad on both profitability and health.
SNDX Financial Highlights
Over the last trailing twelve months SNDX reported a non-GAAP Earnings per Share(EPS) of -3.61. The EPS increased by 0.55% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -56.19% | ||
| ROE | -212.79% | ||
| Debt/Equity | 2.07 |
SNDX Forecast & Estimates
20 analysts have analysed SNDX and the average price target is 38.93 USD. This implies a price increase of 158.84% is expected in the next year compared to the current price of 15.04.
For the next year, analysts expect an EPS growth of 14.48% and a revenue growth 77.13% for SNDX